Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Calithera Biosciences, Inc"
Count: 22
Selected: 0
NCT02197572Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors
NCT05319028Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05275673A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
NCT03057600Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)
NCT04265534KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
NCT03965845A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
NCT03163667CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
NCT02071862Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
NCT04279769Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis
NCT03875313Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
NCT04698681NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial
NCT03428217CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
NCT02771626Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
NCT04607512Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects
NCT04540965Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects
NCT02071888Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
NCT02071927Study of the Glutaminase Inhibitor CB-839 in Leukemia
NCT02944435A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults
NCT03097328Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
NCT03263429Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
NCT05521997Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
NCT04824937Telaglenastat + Talazoparib In Prostate Cancer